ISCHEMIA Trial and the Significance of MI
During the past decade, the treatment of choice for chronic coronary syndromes (CCS) has been a contentious issue. Whether revascularisation, either percutaneous or surgical, or optimal medical therapy, offers better prognosis in terms of mortality, MI, and symptom relief, has yet to be confirmed. T...
Enregistré dans:
Auteurs principaux: | Eduardo A Arias, Félix Damas-de los Santos, Heriberto Ontiveros-Mercado |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Radcliffe Medical Media
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/27f8c08c55f44a4e92f157da82c56f8d |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
par: Joel P Giblett, et autres
Publié: (2020) -
Clinical significance of hsCRP level in acute coronary syndrome
par: V.K. Katyal, et autres
Publié: (2021) -
Reprising an old friend – The Athens QRS score as a predictor of coronary artery disease in patients with intermediate treadmill test during ischemia evaluation
par: Prayaag Kini, et autres
Publié: (2021) -
A study of immediate and long-term results of significant tricuspiud regurgitation after percutaneous mitral balloon valvotomy
par: Remala Archana, et autres
Publié: (2021) -
Clinical profile of patients with qRBBB MI at tertiary care centre
par: Achal Sharma, et autres
Publié: (2021)